Department of Hematology& Bone Marrow Transplantation, Max Superspecialty Hospital, Saket, New Delhi, 110017, India.
Rajiv Gandhi Cancer Institute, New Delhi, India.
Transfus Apher Sci. 2021 Jun;60(3):103075. doi: 10.1016/j.transci.2021.103075. Epub 2021 Feb 3.
Data on convalescent plasma therapy (CPT) in patients of hematological malignancies with severe Covid-19 is scarce.
To study 14-day mortality in patients who received CPT.
PATIENTS & METHODS: Retrospective multicentre observational study conducted in 4 centres treating haematological malignancies across Delhi-national capital region. Total 33 haematological malignancies patients with severe Covid-19 who received CPT were analysed.
The median age of the study cohort was 62 years (18-80 years). Twenty one percent patients had 1 comorbidity, 18 % had 2 comorbidities and 6% patients had 3 and 5 comorbidities each. Twenty four patients were on active therapy. Sixty nine percent of patients required ICU stay. Twenty five patients received plasma therapy within 7 days (early) of diagnosis of Covid-19 infection. Median day of plasma infusion from date of diagnosis of Covid-19 infection was 4 days (range: 2-25 days). Patient who had early initiation of plasma therapy had shorter duration of hospitalisation (12.7 vs 24.3 days, p = 0.000). Overall mortality in the cohort was 45.5%. There was no effect of disease status, active therapy, presence of comorbidity on mortality. There was no difference in the mortality in patients receiving early vs late initiation of plasma therapy or in patients receiving one versus two plasma therapy.
We provide a large series of patients with hematological malignancies and role of CPT in this group.
关于接受恢复期血浆疗法（CPT）的血液恶性肿瘤患者的严重 COVID-19 数据稀缺。
研究接受 CPT 的患者的 14 天死亡率。
在德里-国家首都地区治疗血液恶性肿瘤的 4 个中心进行了回顾性多中心观察性研究。共分析了 33 名接受 CPT 的患有严重 COVID-19 的血液恶性肿瘤患者。
研究队列的中位年龄为 62 岁（18-80 岁）。21%的患者有 1 种合并症，18%有 2 种合并症，6%的患者各有 3 种和 5 种合并症。24 名患者正在接受积极治疗。69%的患者需要入住 ICU。25 名患者在 COVID-19 感染确诊后 7 天内（早期）接受了血浆治疗。从 COVID-19 感染确诊日期起输注血浆的中位数天数为 4 天（范围：2-25 天）。早期开始血浆治疗的患者住院时间更短（12.7 天 vs 24.3 天，p = 0.000）。该队列的总体死亡率为 45.5%。疾病状态、积极治疗、合并症的存在均未对死亡率产生影响。早期与晚期开始血浆治疗或接受一次与两次血浆治疗的患者死亡率无差异。
我们提供了大量患有血液恶性肿瘤的患者，并探讨了 CPT 在该人群中的作用。
